StockNews.AI

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

StockNews.AI • 13 hours

NVSAMGNEXAS
High Materiality7/10

Information

SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a co...

Original source

AI Summary

ADPT reported $277M total revenue for 2025, up 55% from 2024. MRD revenue increased by 46% in 2025; strong clonoSEQ adoption noted. Fourth quarter MRD revenue was $62M, showing 54% growth year-over-year. 2025 marks pivotal growth; plans for continued MRD leadership in 2026. Cash reserves at $227M position ADPT for future investments.

Sentiment Rationale

Strong revenue growth and adoption of clonoSEQ testing suggest positive market reception, comparable to past instances where growth spurred stock appreciation.

Trading Thesis

Continued focus on MRD testing and future product developments can sustain interest and investment in Adaptive Biotechnologies.

Market-Moving

  • ADPT reported $277M total revenue for 2025, up 55% from 2024.
  • MRD revenue increased by 46% in 2025; strong clonoSEQ adoption noted.
  • Fourth quarter MRD revenue was $62M, showing 54% growth year-over-year.

Key Facts

  • ADPT reported $277M total revenue for 2025, up 55% from 2024.
  • MRD revenue increased by 46% in 2025; strong clonoSEQ adoption noted.
  • Fourth quarter MRD revenue was $62M, showing 54% growth year-over-year.
  • 2025 marks pivotal growth; plans for continued MRD leadership in 2026.
  • Cash reserves at $227M position ADPT for future investments.

Companies Mentioned

  • NVS (NVS)
  • AMGN (AMGN)
  • EXAS (EXAS)

Corporate Developments

Given the solid performance metrics and future prospects, the findings significantly influence investor sentiment positively towards ADPT.

Adaptive Biotechnologies Reports Strong Preliminary Financial Results for Q4 and Full Year 2025

SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a leading biotechnology company focused on leveraging the adaptive immune system for innovative clinical products, has announced its preliminary, unaudited results for the fourth quarter and full year ending December 31, 2025. The firm reported impressive revenue figures, showing significant growth in both total revenue and Minimal Residual Disease (MRD) revenue.

Key Financial Highlights

  • Total revenue for Q4 2025 was approximately $72 million, a 51% increase compared to Q4 2024.
  • Full year revenue reached around $277 million, reflecting a 55% growth year over year.
  • MRD revenue for Q4 2025 amounted to approximately $62 million, an increase of 54% from the same period in 2024.
  • For the full year, MRD revenue totaled about $212 million, rising by 46% year over year.
  • Excluding regulatory milestone revenues, MRD revenue grew by 45% for the entire year.
  • The volume of clonoSEQ tests conducted increased by 43% to approximately 30,000 in Q4 2025.
  • Adaptive Biotechnologies ended 2025 with around 105,600 clonoSEQ tests delivered, marking a 39% increase year-over-year.
  • Cash, cash equivalents, and marketable securities stood at approximately $227 million as of December 31, 2025.

Company Outlook and Strategy for 2026

Chad Robins, CEO and co-founder of Adaptive Biotechnologies, stated, “2025 was a pivotal year for Adaptive, marked by accelerating momentum across our MRD business driven by strong growth in clonoSEQ adoption.” He emphasized the company's commitment to extending its leadership in MRD testing and sustaining robust growth in clonoSEQ volume and average selling price (ASP).

Upcoming Financial Disclosure

Adaptive Biotechnologies plans to release comprehensive financial results for Q4 and the full year of 2025 during its earnings call scheduled for February 2026. These detailed results will provide further insight into the company’s financial health and strategic initiatives moving forward.

Forward-Looking Statements

All statements in this announcement other than historical facts are considered forward-looking statements. These include predictions regarding financial outcomes and growth strategies, which are subject to risks and uncertainties. The final 2025 results may differ materially from the preliminary figures disclosed today due to the completion of accounting procedures.

About Adaptive Biotechnologies

Adaptive Biotechnologies is committed to transforming the diagnosis and treatment of diseases through its proprietary immune medicine platform. Focused on the adaptive immune system’s potential, the company develops clinical diagnostics that target a variety of conditions, including cancer and autoimmune disorders. Their goal is to create individually tailored immune-driven solutions to improve patient outcomes.

Related News